clinicians preference when semaglutide is not suitable For patients with #obesity, semaglutide, a glucagon-like peptide-1 receptor agonist, approved for weight management as a once-weekly subcutaneous injection. In a previous trial, oral at a dose of 50 mg Benefits of Semaglutide GLP-1 |

Ozempic may contribute to an increased risk for thyroid c-cell tumors, acute pancreatitis, gallbladder disease, hypoglyceia, acute kidney injury, severe GI side effects, and an increased risk for worsening of diabetic retinopathy in people with type 2 diabetes

Insurance coverage is substantially better for diabetes indications compared to weight management

When restriction has already been part of the story, adding a medication that suppresses appetite is not a neutral intervention. Gastrointestinal Conditions That Require Caution Because GLP-1 medications slow gastric emptying and affect gut motility, certain GI conditions need special caution

IUBMB life 60 , 790797, doi: 10.1002/iub.124 (2008)

Nesfatin-1-regulated oxytocinergic signaling in the paraventricular nucleus causes anorexia through a leptin-independent melanocortin pathway

Is GLOW the same as KLOW